Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $125.46 USD
Change Today -1.16 / -0.92%
Volume 726.0K
As of 12:24 PM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

medivation inc (MDVN) Snapshot

Open
$127.00
Previous Close
$126.62
Day High
$127.39
Day Low
$121.39
52 Week High
03/23/15 - $141.58
52 Week Low
04/28/14 - $55.25
Market Cap
9.8B
Average Volume 10 Days
722.5K
EPS TTM
$2.95
Shares Outstanding
78.2M
EX-Date
07/27/99
P/E TM
42.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVATION INC (MDVN)

medivation inc (MDVN) Related Businessweek News

View More BusinessWeek News

medivation inc (MDVN) Details

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company’s prostate cancer clinical trials include STRIVE, which is in Phase II clinical trial; PROSPER and EMBARK for which enrollment is ongoing for the Phase III clinical trial; PLATO, which is in the Phase IV clinical trial; AFFIRM and PREVAIL that have completed enrollment for the Phase III clinical trial; and TERRAIN for which enrollment is completed for the Phase II clinical trial. Its breast cancer clinical trials comprise AR+, TNBC, ER+ or PgR+ and HER2 Normal, and AR+ HER2 Amplified that are in Phase II clinical trials. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. The company is headquartered in San Francisco, California.

485 Employees
Last Reported Date: 02/25/15

medivation inc (MDVN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $750.0K
Chief Medical Officer
Total Annual Compensation: $480.4K
General Counsel and Corporate Secretary
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

medivation inc (MDVN) Key Developments

Medivation, Inc. and Astellas Pharma Inc. Announces Encouraging Results from Phase II Prostate Cancer Trial

Medivation, Inc. and Astellas Pharma Inc. have announced encouraging results from the Phase II STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared with bicalutamide (Hazard Ratio = 0.24; 95% Confidence Interval, 0.18-0.32; p Grade 3 or higher cardiac adverse events were reported in 5.1% of enzalutamide-treated patients versus 4.0% of bicalutamide-treated patients. One seizure was reported in the trial in the enzalutamide-treated group and none in the bicalutamide-treated group. The most common side effects noted more frequently in the enzalutamide-treated versus bicalutamide-treated patients included fatigue, back pain, hot flush, fall, hypertension, dizziness, and decreased appetite, consistent with the known safety profile of enzalutamide. The STRIVE study is the second of two head-to-head studies of enzalutamide versus bicalutamide, the first of which was TERRAIN. The Phase II STRIVE trial enrolled 396 castration-resistant prostate cancer patients in the US. The trial randomized 257 patients with metastatic prostate cancer and 139 patients with non-metastatic prostate cancer whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The primary endpoint of the trial was progression-free survival, defined as time from randomization to radiographic (bone or soft tissue) progression, PSA progression (defined by Prostate Cancer Working Group 2 criteria), or death due to any cause, whichever occurs first. The trial was designed to evaluate enzalutamide at a dose of 160 mg taken once daily versus bicalutamide at a dose of 50 mg taken once daily, the approved dose in combination with a LHRH analogue.

Astellas Pharma Inc. and Medivation, Inc. Announce Topline Results from the Phase 2 STRIV Trial

Astellas Pharma Inc. and Medivation, Inc. announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. The study achieved its primary endpoint demonstrating a statistically significant increase in progression-free survival (PFS) for enzalutamide compared with bicalutamide (Hazard Ratio = 0.24; 95% Confidence Interval, 0.18-0.32. The median time on treatment in the STRIVE trial was 14.7 months in the enzalutamide group versus 8.4 months in the bicalutamide group. Serious adverse events were reported in 29.4% of enzalutamide-treated patients and 28.3% of bicalutamide-treated patients. Grade 3 or higher cardiac adverse events were reported in 5.1% of enzalutamide-treated patients versus 4.0% of bicalutamide-treated patients. One seizure was reported in the trial in the enzalutamide-treated group and none in the bicalutamide-treated group. The most common side effects noted more frequently in the enzalutamide-treated versus bicalutamide-treated patients included fatigue, back pain, hot flush, fall, hypertension, dizziness, and decreased appetite, consistent with the known safety profile of enzalutamide.

Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress

Astellas Pharma Inc. and Medivation, Inc. announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of enzalutamide in chemotherapy-naive metastatic CRPC. The data were presented during a plenary session at the 2015 European Association of Urology (EAU) Congress in Madrid, Spain. The Phase 2 TERRAIN trial enrolled 375 patients in North America and Europe. The trial enrolled patients with metastatic prostate cancer whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analogue therapy or following surgical castration. The primary endpoint of the trial was progression-free survival (PFS), defined as time from randomization to centrally confirmed radiographic progression, skeletal-related event, initiation of new anti-neoplastic therapy or death, whichever occurred first. The trial was designed to evaluate enzalutamide at a dose of 160 mg taken orally once daily versus bicalutamide at a dose of 50 mg taken once daily, the approved dose in combination with an LHRH analogue.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDVN:US $125.46 USD -1.16

MDVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $9.03 USD -0.019
Insys Therapeutics Inc $57.92 USD +1.50
Pfizer Ltd/India 2,019 INR -26.75
Sanofi India Ltd 3,151 INR -3.80
Seattle Genetics Inc $34.97 USD -0.50
View Industry Companies
 

Industry Analysis

MDVN

Industry Average

Valuation MDVN Industry Range
Price/Earnings 40.3x
Price/Sales 14.3x
Price/Book 22.8x
Price/Cash Flow 37.1x
TEV/Sales 13.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVATION INC, please visit www.medivation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.